Gene therapy for Alzheimer's disease using virally delivered Aβ variants
使用病毒传递的 Aβ 变体进行阿尔茨海默氏病的基因治疗
基本信息
- 批准号:10609343
- 负责人:
- 金额:$ 13.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-15 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:APP-PS1AducanumabAftercareAgeAlzheimer&aposs DiseaseAlzheimer&aposs disease therapyAmyloidAmyloid beta-ProteinAntibodiesBiophysical ProcessBirthBrainCell membraneChromatographyChronicDataDiseaseEngineeringExtracellular SpaceGene Expression ProfilingGene Transduction AgentGenesHalf-LifeHistologicIn VitroLifeMemantineMusNeuroimmuneNeuronsOutcomePenetrationPeptidesPhasePreventionPreventive treatmentReactionRouteSpectrum AnalysisTechnologyTestingTherapeuticTherapeutic UsesToxic effectVariantViralWorkadeno-associated viral vectoranalytical methodcognitive functioncomparison interventiondelivery vehicledosagegamma secretasegene therapyin vivoinhibitormouse modelnovelpeptide drugpreventprotein misfoldingresponsetau Proteins
项目摘要
SUMMARY
The continuing saga of anti-Ab antibody aducanumab has produced the first positive phase 3 outcome for
Alzheimer's disease (AD) since memantine was approved in 2003. This promising, albeit controversial, result
has breathed new life into the therapeutic potential for Ab-lowering strategies and legitimized the ongoing
exploration of other means to chronically and safely mitigate Ab. Past work had shown that small peptide
inhibitors can be readily tailored to prevent Ab aggregation, but in vivo delivery of peptide-based drugs was
limited by short half-life and poor brain penetration. We have identified two Ab sequence variants that meet
criteria for potential therapeutic use, as they 1) prevent aggregation of WT Ab in vitro, 2) promote disassembly
of Ab existing fibrils, 3) mitigate toxicity of Ab oligomers, and importantly, 4) do not self-aggregate. To deliver
these peptides in vivo, we have developed a novel mini-gene to express our variant peptides at the plasma
membrane where they are released into the extracellular space by g-secretase cleavage. By packaging this
minigene into an AAV vector that is injected into APP/PS1 mice, our pilot data show that viral expression of
variant Ab lowers Ab load and delays plaque formation. The current proposal will build on these results
through the following specific aims. First, we will decipher the biophysical mechanism of interactions between
variant and wild type Aβ peptides. We will use analytical methods of CD spectroscopy, SEC chromatography,
EM, and antibody profiling to define the structural mechanism by which our variants prevent/reverse
aggregation of wild-type Ab. Second, we will determine how dosage, timing and route of variant Aβ
administration influence efficacy in vivo. We will use viral strategies to compare interventional treatment after
amyloid onset with preventative treatment starting at birth, determine the lowest effective ratio of variant:wild-
type Ab needed to modify plaque formation and cognitive function, and test whether delivery through the CSF
can match the effect of neuronal transduction. Third, we will interrogate the neuroimmune reaction to variant
Aβ as an accomplice to plaque reduction. We will use histological and transcriptional profiling to assess
whether a neuroimmune response to either the variant peptide or its AAV carrier contribute to plaque
prevention in vivo, and if the neuroimmune response changes with age. Finally, we will test the potential for
variant Aβ to slow AD aggregate seeding. We anticipate that variant Ab will slow seeding by AD Ab extracts,
but will more importantly test whether variant Ab can assuage cross-seeding of tau in amyloid-bearing mice. If
successful, this strategy for self-inhibition may also be applicable to other protein misfolding diseases where
peptide treatments have been eschewed for technical reasons that can now be overcome through
expression engineering and viral technology.
总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOANNA L JANKOWSKY其他文献
JOANNA L JANKOWSKY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOANNA L JANKOWSKY', 18)}}的其他基金
TMEM106b as a lysosomal adaptor to influence brain aging and tau pathogenesis
TMEM106b 作为溶酶体适配器影响大脑衰老和 tau 发病机制
- 批准号:
10583546 - 财政年份:2021
- 资助金额:
$ 13.98万 - 项目类别:
TMEM106b as a lysosomal adaptor to influence brain aging and tau pathogenesis
TMEM106b 作为溶酶体适配器影响大脑衰老和 tau 发病机制
- 批准号:
10413976 - 财政年份:2021
- 资助金额:
$ 13.98万 - 项目类别:
Gene therapy for Alzheimer's disease using virally delivered Aβ variants
使用病毒传递的 Aβ 变体进行阿尔茨海默氏病的基因治疗
- 批准号:
10316624 - 财政年份:2021
- 资助金额:
$ 13.98万 - 项目类别:
TMEM106b as a lysosomal adaptor to influence brain aging and tau pathogenesis
TMEM106b 作为溶酶体适配器影响大脑衰老和 tau 发病机制
- 批准号:
10172237 - 财政年份:2021
- 资助金额:
$ 13.98万 - 项目类别:
Plasticity of the entorhinal-hippocampal circuit as a vulnerability in AD
内嗅海马回路的可塑性是 AD 的一个弱点
- 批准号:
10078733 - 财政年份:2017
- 资助金额:
$ 13.98万 - 项目类别:
Plasticity of the entorhinal-hippocampal circuit as a vulnerability in AD
内嗅海马回路的可塑性是 AD 的一个弱点
- 批准号:
9438665 - 财政年份:2017
- 资助金额:
$ 13.98万 - 项目类别:
Deconstructing the pathogenic effect of APP in memory circuits
解构APP对记忆回路的致病作用
- 批准号:
8938903 - 财政年份:2015
- 资助金额:
$ 13.98万 - 项目类别:
Deconstructing the pathogenic effect of APP in memory circuits
解构APP对记忆回路的致病作用
- 批准号:
9104241 - 财政年份:2015
- 资助金额:
$ 13.98万 - 项目类别:
Selective neuronal silencing to study hippocampal neurogenesis in depression
选择性神经元沉默研究抑郁症中海马神经发生
- 批准号:
8687749 - 财政年份:2013
- 资助金额:
$ 13.98万 - 项目类别:
Selective neuronal silencing to study hippocampal neurogenesis in depression
选择性神经元沉默研究抑郁症中海马神经发生
- 批准号:
8564283 - 财政年份:2013
- 资助金额:
$ 13.98万 - 项目类别:
相似海外基金
IU/JAX/Pitt MODEL-AD: Murinizing Aducanumab
IU/JAX/Pitt MODEL-AD:Murinizing Aducanumab
- 批准号:
10094809 - 财政年份:2016
- 资助金额:
$ 13.98万 - 项目类别:














{{item.name}}会员




